Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stratified analysis identifies HIF-2α as a therapeutic target for highly immune-infiltrated melanomas.
Huang AY, Burke KP, Porter R, Meiger L, Fatouros P, Yang J, Robitschek E, Vokes N, Ricker C, Rosado V, Tarantino G, Chen J, Aprati TJ, Glettig MC, He Y, Wang C, Fu D, Ho LL, Galani K, Freeman GJ, Buchbinder EI, Stephen Hodi F, Kellis M, Boland GM, Sharpe AH, Liu D. Huang AY, et al. Among authors: sharpe ah. bioRxiv [Preprint]. 2024 Oct 30:2024.10.29.620300. doi: 10.1101/2024.10.29.620300. bioRxiv. 2024. PMID: 39554029 Free PMC article. Preprint.
Immune checkpoint receptors in autoimmunity.
Burke KP, Patterson DG, Liang D, Sharpe AH. Burke KP, et al. Among authors: sharpe ah. Curr Opin Immunol. 2023 Feb;80:102283. doi: 10.1016/j.coi.2023.102283. Epub 2023 Jan 28. Curr Opin Immunol. 2023. PMID: 36709596 Free PMC article. Review.
Tracking tumor-specific CD8+ T cell responses.
Burke KP, Markson SC, Sharpe AH. Burke KP, et al. Among authors: sharpe ah. Trends Immunol. 2023 May;44(5):326-328. doi: 10.1016/j.it.2023.03.012. Epub 2023 Apr 7. Trends Immunol. 2023. PMID: 37031062 Free PMC article.
Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models.
Datta M, Chatterjee S, Perez EM, Gritsch S, Roberge S, Duquette M, Chen IX, Naxerova K, Kumar AS, Ghosh M, Emblem KE, Ng MR, Ho WW, Kumar P, Krishnan S, Dong X, Speranza MC, Neagu MR, Iorgulescu JB, Huang RY, Youssef G, Reardon DA, Sharpe AH, Freeman GJ, Suvà ML, Xu L, Jain RK. Datta M, et al. Among authors: sharpe ah. Proc Natl Acad Sci U S A. 2023 Feb 7;120(6):e2219199120. doi: 10.1073/pnas.2219199120. Epub 2023 Feb 1. Proc Natl Acad Sci U S A. 2023. PMID: 36724255 Free PMC article.
Targeting RGMb interactions: Discovery and preclinical characterization of potent anti-RGMb antibodies blocking multiple ligand bindings.
Meira M, Frey A, Chekkat N, Rybczynska M, Sellam Z, Park JS, Gazzaniga FS, Parmentier A, Le Gall M, Freeman GJ, Kasper DL, Sharpe AH, Rambeaux E, Shamshiev A. Meira M, et al. Among authors: sharpe ah. MAbs. 2024 Jan-Dec;16(1):2432403. doi: 10.1080/19420862.2024.2432403. Epub 2024 Nov 26. MAbs. 2024. PMID: 39588913 Free PMC article.
Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model.
Iorgulescu JB, Ruthen N, Ahn R, Panagioti E, Gokhale PC, Neagu M, Speranza MC, Eschle BK, Soroko KM, Piranlioglu R, Datta M, Krishnan S, Yates KB, Baker GJ, Jain RK, Suvà ML, Neuberg D, White FM, Chiocca EA, Freeman GJ, Sharpe AH, Wu CJ, Reardon DA. Iorgulescu JB, et al. Among authors: sharpe ah. Front Immunol. 2023 Dec 28;14:1297932. doi: 10.3389/fimmu.2023.1297932. eCollection 2023. Front Immunol. 2023. PMID: 38213329 Free PMC article.
LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity.
Ngiow SF, Manne S, Huang YJ, Azar T, Chen Z, Mathew D, Chen Q, Khan O, Wu JE, Alcalde V, Flowers AJ, McClain S, Baxter AE, Kurachi M, Shi J, Huang AC, Giles JR, Sharpe AH, Vignali DAA, Wherry EJ. Ngiow SF, et al. Among authors: sharpe ah. Cell. 2024 Aug 8;187(16):4336-4354.e19. doi: 10.1016/j.cell.2024.07.018. Cell. 2024. PMID: 39121847
LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity.
Andrews LP, Butler SC, Cui J, Cillo AR, Cardello C, Liu C, Brunazzi EA, Baessler A, Xie B, Kunning SR, Ngiow SF, Huang YJ, Manne S, Sharpe AH, Delgoffe GM, Wherry EJ, Kirkwood JM, Bruno TC, Workman CJ, Vignali DAA. Andrews LP, et al. Among authors: sharpe ah. Cell. 2024 Aug 8;187(16):4355-4372.e22. doi: 10.1016/j.cell.2024.07.016. Cell. 2024. PMID: 39121848
393 results